Clinical trials: Uric Acid
Gout
Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
There is a mounting and clear association between hyperuricaemia, gout and the presence of traditional cardiovascular (CV) risk factors and CV event-equivalent conditions such as chronic kidney disease, metabolic syndrome, and…
- Trial name
- FORWARD (NCT02500641)
- Testing
- Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine
- Where
- 26 sites in Germany, Italy and 4 more
- Volunteers
- 196 people
- Sponsor
- Menarini International Operations Luxembourg SA
Hyperuricemia
Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma
The primary objective was to evaluate the efficacy of rasburicase in terms of prevention and treatment of hyperuricemia related to Tumor Lysis Syndrome (TLS) in 2 populations of adult patients, previously treated or not with…
- Trial name
- GRAAL2 (NCT00664144)
- Testing
- Rasburicase (SR29142)
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 33 people
- Sponsor
- Sanofi
Gout
Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), in reducing serum urate levels in subjects with gout.
- Trial name
- NCT00174967
- Testing
- Febuxostat
- Volunteers
- 153 people
- Sponsor
- Takeda
Gout
Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.
The purpose of the study is to assess the effect of PF-06743649 in lowering serum uric acid in subjects suffering from gout following 14 days of dosing, as well as assessing safety and tolerability.
- Trial name
- NCT02187029
- Testing
- PF-06743649
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Gout
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
The study will be conducted in two parts. The first is a parallel-group design, evaluating doses of 40 mg, 80 mg or 120 mg BCX-4208.
- Trial name
- NCT00985127
- Testing
- BCX4208
- Where
- 24 sites in United States
- Volunteers
- 99 people
- Sponsor
- BioCryst Pharmaceuticals
Lithiasis
Study of the Crystallization Inhibition Capacity of the Uric Acid in Urine in a Group of Lithiasic Patients After Intake of a Food Supplement
Renal lithiasis affects a wide range of the population, ranging from 4 to 15% according to the population sample studied. Among all stones, it is estimated that uric stones account for between 10 and 15% of all cases and…
- Trial name
- NCT03483532
- Testing
- Lit Control pH Up, dry cocoa extract
- Where
- Spain
- Volunteers
- 54 people
- Sponsor
- Devicare S.L.
Hyperuricemia
Prevalence of Hyperuricemia in Pakistan
The prevalence of hyperuricemia has rarely been investigated in developing countries Hyperuricemia, or raised serum uric acid (SUA), is the condition closely associated with gout due to the deposition of monosodium urate crystals…
- Trial name
- NCT03473444
- Where
- Pakistan
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- OBS Pakistan